Modern medicine loves to brag about being evidence-based. Fair enough. But here’s the awkward follow-up question: evidence based on whom? For decades, too much clinical research leaned heavily on male participants, male animals, and male-centered assumptions. Even now, while women’s participation has improved overall, the picture is far from neat and tidy. In some fields, women remain underrepresented. In others, women are included but the data are not analyzed carefully by sex. And when that happens, medicine risks building treatment decisions on an incomplete map.
That matters because women are not simply “smaller men with better handbags.” Biology, hormones, body composition, metabolism, immune responses, and even symptom patterns can differ in ways that affect diagnosis, dosing, safety, and outcomes. When women are missing from clinical trialsor when their results are buried in the statistical basementpatients and clinicians are left to make decisions with too many blank spaces. That is not precision medicine. That is guesswork wearing a lab coat.
The History Behind the Gap
To understand why women are underrepresented in clinical trials, it helps to know that this wasn’t an accident that floated in on a light breeze. It was baked into research culture and policy for years. In 1977, the FDA recommended excluding women of childbearing potential from Phase I and early Phase II drug trials. The goal was to protect potential pregnancies after tragedies involving drugs such as thalidomide. The intention may have sounded cautious, but the real-world effect was broad exclusion. In practice, many women were kept out of early research altogether.
That history mattered. When women are excluded from the earliest stages of drug development, the research pipeline starts skewed from day one. Scientists learn how a treatment behaves in men first, then try to apply that knowledge more broadly later. By the time a drug reaches the market, the evidence may still be stronger for male participants than for female patients who will also use it.
The good news is that policy did change. The NIH Revitalization Act of 1993 made inclusion of women and minorities in NIH-funded clinical research a legal requirement. The FDA also moved toward stronger guidance on studying sex differences. Those changes improved representation substantially. Today, women account for roughly half of participants in NIH-supported clinical research. That is real progress, and it deserves credit.
But progress is not the same as mission accomplished. Averages can be sneaky little things. They can look fine overall while still hiding major gaps in specific diseases, trial phases, and patient populations. In other words, medicine has upgraded from “women largely missing” to “women still unevenly represented,” which is better, but not exactly parade-worthy.
Why Underrepresentation Still Exists
One of the biggest misconceptions in women’s health research is that the problem is solved because some modern trials include many women. In reality, underrepresentation is often condition-specific. Some trial areas do fairly well. Others do not. Cardiovascular research is one of the most commonly cited trouble spots. That is especially concerning because heart disease remains a major cause of illness and death in women.
Heart failure trials offer a clear example. In one systematic review highlighted by the National Heart, Lung, and Blood Institute, the average participant age was 65 and only 27% of participants were women. That is a huge mismatch for a condition that affects large numbers of women, especially older women. If your trial population does not resemble your real-world patient population, the results become harder to generalize. That is science’s version of buying shoes based on someone else’s feet.
Oncology has its own problems. A study of randomized trials in colorectal and lung cancer found that the proportion of female patients enrolled was, on average, 6.8% lower than the proportion of women in the disease population. That may not sound dramatic at first glance, but across large trial programs, that gap can translate into weaker evidence for treatment responses, side effects, and long-term outcomes in women.
There is also a second problem that gets less public attention: women may be included in trials, but sex-specific analysis is often weak or incomplete. That means researchers report how many women participated, then fail to examine whether efficacy, adverse events, or dropout rates differed by sex. In one review of ophthalmology trials tied to FDA approvals, most trials reported sex-disaggregated demographics, yet few performed sex- or gender-based analyses for primary outcomes, secondary outcomes, or adverse events. Translation: women showed up, but the science did not always bother to ask whether their results were different.
Why This Is a Problem for Drug Safety and Effectiveness
The most obvious issue is safety. If a drug is studied mainly in men, researchers may miss sex-related differences in metabolism, absorption, or side effects. The FDA’s actions on zolpidem are a famous reminder. After reviewing evidence on next-morning impairment, the agency required lower recommended doses for women for certain zolpidem products. That change underscored a basic truth: women and men do not always process medicines the same way.
Safety is only one piece of the puzzle. Effectiveness matters too. A drug can technically “work” overall while still working differently across subgroups. Women may benefit more, less, or in different ways than men depending on the condition, the endpoint, and the therapy. If trials do not enroll enough women or analyze outcomes properly, those differences can stay hidden. Then doctors prescribe based on partial information, and women become unpaid post-marketing test participants. That is a terrible job description.
Symptom patterns add another layer. Women do not always present disease the same way men do. Cardiovascular disease is a classic example. If diagnostic criteria and treatment strategies are shaped by male-dominant evidence, women may be diagnosed later, treated differently, or told their symptoms are something else entirely. When research evidence is uneven, bias in clinical care gets a convenient hiding place.
Underrepresentation also affects devices, not just drugs. Medical devices tested in populations that do not reflect real-world female patients may perform differently once they are widely used. That can influence everything from fit and durability to complication rates and patient outcomes. In short, lack of representation does not just weaken academic papers; it can shape what happens in exam rooms, emergency departments, infusion centers, and operating suites.
The Problem Starts Before Human Trials
If this were only a clinical trial problem, fixing it would already be challenging. Unfortunately, the issue starts earlier. NIH has noted that while women now make up roughly half of NIH-supported clinical research participants, basic and preclinical biomedical research has often focused on male animals and cells. That means scientists can begin building theories of disease and treatment on sex-skewed foundations before a single human volunteer signs a consent form.
This matters because preclinical work shapes what questions are asked later, which drugs move forward, which doses look promising, and which side effects researchers watch for. If female biology is not adequately studied upstream, the downstream trial may already be operating with blind spots. By the time researchers say, “Oops, maybe sex matters,” the early design decisions are already baked in.
That is why the NIH’s emphasis on sex as a biological variable is so important. Considering sex in study design, data collection, analysis, and reporting improves rigor and generalizability. Or, put less formally, it helps science stop tripping over its own avoidable assumptions.
Women Are Not One Group
Another crucial point: “women” is not a single experience. Women of color, low-income women, rural women, older women, pregnant women, and women with disabilities can face layered barriers to clinical trial participation. A trial may look reasonably balanced by sex on paper while still failing to include the women most affected by a disease.
Researchers at Brigham and Women’s Hospital and Harvard have argued that underrepresentation is often significantly more acute for women of color. That matters because the absence of intersectional data creates an absence of knowledge. If researchers know how many women participated and how many Black participants participated but do not report how many Black women participated, important differences can remain invisible.
This is where health equity and research quality collide. Better representation is not just a fairness slogan. It is a scientific requirement. If the evidence base does not reflect the people who will actually use a drug or device, the evidence base is weaker. Full stop.
What Keeps Women Out of Trials?
Some barriers are structural. Trial sites may be far away, concentrated in large academic centers, or scheduled in ways that clash with work and caregiving. For many women, participation is not blocked by lack of interest; it is blocked by logistics. Childcare, transportation, time off work, digital access, and insurance-related hassles can all shrink the pool of who can realistically enroll and stay enrolled.
Some barriers come from eligibility criteria. Trials may exclude pregnant women, women who could become pregnant, or women with multiple chronic conditions. On paper, these rules may be designed to reduce risk or simplify the data. In practice, they can also remove large numbers of real-world patients from research. The end result is a trial population that looks cleaner than actual clinical practice and much less useful because of it.
Then there is trust. Communities that have experienced discrimination, neglect, or exploitation in health care and research may hesitate to join clinical trials. That hesitation is not irrational. It is learned. Fixing it requires long-term community engagement, transparent communication, diverse research teams, and study designs that respect participants’ time and realities.
Finally, investigator habits matter. If clinicians do not tell women about trial opportunities, assume they will decline, or fail to recognize the importance of balanced recruitment, underrepresentation continues without anyone needing to post a giant “No Women Allowed” sign. Bias can be subtle, but its consequences are not.
How Clinical Trials Can Do Better
The goal is not to force every trial into perfect demographic symmetry. That is not always realistic or scientifically necessary. The goal is to make trial populations appropriate to the disease being studied and to analyze outcomes in ways that produce clinically useful evidence for women.
1. Recruit for representativeness, not convenience
If a disease affects women heavily, the trial should reflect that reality. Recruitment targets should be tied to disease prevalence, not just who is easiest to enroll fastest.
2. Analyze results by sex from the start
Sex-specific analyses should be prespecified whenever relevant, not treated like an optional bonus feature researchers remember at the end. If differences appear in efficacy, dosing, or adverse events, clinicians need that information before a product is widely used.
3. Remove practical barriers
Transportation support, childcare help, flexible scheduling, decentralized visits, and fair compensation can make a major difference. Trial access should not depend on having spare time, spare money, and a very understanding boss.
4. Improve community engagement
People are more likely to join research when communication is clear, respectful, and culturally competent. Diverse study teams and trusted community partnerships can help turn recruitment from a cold pitch into a credible invitation.
5. Report intersectional data
Knowing how women as a whole fared is useful. Knowing how older women, Black women, Hispanic women, and other subgroups fared can be even more useful. Better reporting creates better medicine.
What This Looks Like in Real Life: Experiences Behind the Statistics
Statistics tell us the scale of the problem, but experiences show why it hits so hard. Picture a woman in her late 50s with symptoms of heart disease that do not match the dramatic movie scene of a man clutching his chest and collapsing over a steak dinner. Her symptoms are fatigue, shortness of breath, nausea, and back pain. They are real, serious, and medically important. But when the evidence base for diagnosis and treatment is shaped too heavily by male participants, women like her may be recognized later or treated less aggressively. The problem is not that her body failed to read the textbook. The problem is that the textbook was incomplete.
Now picture a younger woman managing work, school drop-offs, and an aging parent. She hears about a clinical trial, maybe from a specialist, maybe from a friend, maybe not at all. She is interested. She wants better options and likes the idea of helping future patients. Then reality barges in. The study visits are across town. The available appointment times are mid-morning on weekdays. Parking is expensive. She would need childcare. She might lose hourly wages. Suddenly, the trial is not an opportunity. It is a logistical obstacle course with a consent form attached.
For women of color, the experience can be even more layered. There may be justified mistrust rooted in historical abuse and present-day inequities. There may be fewer referrals, fewer clinicians who look like them, or fewer study materials written in ways that feel accessible and respectful. When people hear “underrepresentation,” it can sound abstract. In practice, it often means women are asked to trust systems that have not consistently earned that trust.
Researchers feel this tension too. Many trial teams know they need broader enrollment but are working inside systems built for speed, not inclusion. Study budgets may not cover transportation or childcare. Eligibility criteria may be inherited from earlier protocols. Trial sponsors may want tidy data and quick recruitment, even if that produces a narrow participant pool. So staff members end up trying to solve structural problems with phone calls, reminder texts, and heroic levels of patience.
Clinicians see the downstream impact when treatments enter the real world. A doctor may prescribe a drug approved through solid research, yet still wonder whether the evidence fully applies to the woman sitting in front of theman older patient, a pregnant patient, a patient with multiple chronic conditions, or a patient whose lived reality was barely reflected in the trial population. That uncertainty is frustrating for providers, but it is riskier for patients.
And then there is the emotional piece. Many women have had the experience of feeling dismissed in health care. Add underrepresentation in clinical trials, and it can reinforce a bigger message: medicine is paying attention, just not always to you. That is why better inclusion matters beyond statistics. It tells women their bodies are worth studying carefully, their outcomes count, and their health is not a side note to be analyzed later if somebody gets around to it.
When clinical trials improve, women notice. Recruitment feels more respectful. Participation feels more possible. Results feel more relevant. That is the goalnot just more women in spreadsheets, but better evidence in real life.
Final Takeaway
Women’s inclusion in clinical research has improved dramatically since the bad old days of routine exclusion. That progress matters. But the bigger truth is that representation is still uneven, sex-specific analysis is still too inconsistent, and important groups of women remain underserved by the evidence base. When women are underrepresented in clinical trials, medicine risks missing differences in safety, dosing, symptoms, and effectiveness. That weakens care for half the population and undermines the very idea of evidence-based treatment.
The fix is not mysterious. Enroll women in numbers that reflect disease burden. Reduce practical barriers. Design smarter protocols. Analyze data by sex. Report results transparently. And remember that women are not a niche subgroup. They are patients, participants, and a massive part of the real world that medicine is supposed to serve. Clinical research works best when it studies the people who will actually use the treatments. Which, yes, includes women. Revolutionary concept, apparently.
